Dataset from A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00008259
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered
as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of
age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder
(ADHD).
创建时间：
2026-03-25
